All In Biotech

Drug Trial Radar · NCT05421013

Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC

An Open Label, Dose Escalation Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Subjects With Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

9

Actual

Start

Aug 1, 2022

Primary completion

Mar 29, 2023

Study completion Mar 29, 2023

Sponsor

Lead sponsor
SirnaomicsIndustry
Sponsor type
Industry
First posted
Jun 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open label, dose escalation to evaluate safety.

Conditions

  • Facial isSCC

Interventions

  • STP705Drug

    STP705 targets TGFB-1 and COX-2 mRNA respectively.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants With Histological Clerance of Treated isSCC Lesion at the End of TreatmentTime frame: 21 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Center for Clinical and Cosmetic Research

    Aventura, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.